A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE).

Trial Profile

A Phase III, Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Efficacy and Safety of Dalcetrapib on Lipids, Lipoproteins, Apolipoproteins and Markers of CV Risk in Patients Hospitalized for an Acute Coronary Syndrome (ACS) When Treatment is Initiated Within 1 Week After an ACS (Dal-ACUTE).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Dalcetrapib (Primary)
  • Indications Acute coronary syndromes; Dyslipidaemias
  • Focus Registrational; Therapeutic Use
  • Acronyms Dal-ACUTE
  • Sponsors Roche
  • Most Recent Events

    • 07 Nov 2012 Primary endpoint 'HDL-cholesterol-level' has been met.
    • 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
    • 07 May 2012 Status changed from recruiting to discontinued as reported by Roche.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top